Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05380856
Other study ID # OdenseOUH
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 26, 2023
Est. completion date March 1, 2027

Study information

Verified date November 2023
Source Odense University Hospital
Contact Hanne Kobberø
Phone 004565414400
Email hanne.kobberoe2@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and a 3-4 weeks test period patients with more than 50% improvement in the key bladder diary variables will have the IPG implanted. After a month of optimization patients will into two groups: IPG ON or IPG OFF. Period of randomization: four months. Number anticipated to be included: 60 patients


Description:

Patients with MS often suffer from pelvic-organ dysfunctions, i.e. lower urinary tract (LUT), bowel and sexual dysfunction, aside their cerebral affection. Sacral neuromodulation (SNM) is a reversible minimal invasive procedure affecting the function of the aforementioned pelvic organs. Changes in bladder, bowel and sexual function will be monitored. Primary outcome: Success of SNM for lower urinary tract dysfunction as improvement of at least 50% in the key bladder diary variables (i.e. number of voids and/or number of leakages, post void residual) compared to the baseline values. Secondary outcome: To assess the changes in bladder, bowel and sexual function due to SNM by using subjective patient reported outcome measures, quality of life and global assessment score, - To assess the changes in urodynamic variables, - To assess the safety of SNM for NLUTD and - To register the implantation characteristics and the need for reprogramming Data will be collected at Baseline 1: At inclusion Baseline 2: At evaluation after a three weeks test period Baseline 3: At randomization Baseline 4: At the end of study The time frame of the RCT is six months Patients with improvements of bowel symptoms only will be excluded from the trial but followed with the same questionnaires for the same time. The patients will be followed-up every 6 months for a total of 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 1, 2027
Est. primary completion date March 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Refractory neurogenic lower urinary tract dysfunction (nLUTD) defined by visual analogue scale on treatment satisfaction ranging from 0 to 100 (100 means maximal satisfaction with the current treatment). All patients indicating satisfaction less than 50 are considered non-responders/having refractory overactive bladder (OAB) to current treatment - No effect of medical treatment defined by antimuscarinics, beta3-agonist and alpha-blocker. - Patients having refractory nLUTD who intend to try SNM for relief of their symptoms - Expanded Disability Status Scale (EDSS) < 5 and no progression of neurological disease within 6 months - Written informed consent - Able to understand the information given about the project Exclusion Criteria: - EDSS > 5, neurological disease with severe progression within the last 6 months and/or unable to manage the electronic devices - Age < 18 years - Any other urological pathology but nLUTD - Bladder Pain Syndrome/Interstitial cystitis - Any other intestinal or gynecological pathology but neurological conditional symptoms - Current pelvic malignancy or clinically significant pelvic mass - Previous pelvis radiotherapy - Bladder injections with botulinum neurotoxin type A within 6 months before inclusion in trial - Unable to manage the electronic devices - Inability to give an informed consent

Study Design


Intervention

Device:
Turning ON the neuromodulator
IPG on
Turning OFF the neuromodulator
IPG OFF

Locations

Country Name City State
Denmark Odense University Hospital Odense Fyn

Sponsors (4)

Lead Sponsor Collaborator
Odense University Hospital Aarhus University Hospital, University Hospital Ostrava, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Rate of adverse events evaluated by the Medical Device Coordination Group, (MDCG)-202010/1, safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017/745 Six months
Other Global assessment scale 5 point Likert scale evaluated by: Very satisfied - satisfied - neutral - unsatisfied - very unsatisfied Six months
Other Implantation Characteristics The lowest stimulation value in mA will be monitored and number of the re-programming Six months
Primary Success of SNM for neurogenic lower urinary tract dysfunction Success is defined as improvement of at least 50% in the key bladder diary variables, i.e. number of voids and/or number of leakages, post void residual volumen, compared to the baseline values using BLADDER DIARY for three days before inclusion and at evaluation. Six months
Primary Male bladder function Male lower urinary tract symptoms (MLUTS) by standard International Consultation on Incontinence Questionnaire (ICIQ)-MLUTS 10/06.
Scale ranges from 0 to 44 points. Higher score indicate greater impact of individual symptoms for the patient.
Changes will be compared to basal data.
Six months
Primary Female bladder function Female lower urinary tract symptoms (FLUTS) by standard questionnaire ICIQ-FLUTS 12/07.
Scale ranges from 0 to 48 points. Higher score indicate greater impact of individual symptoms for the patient.
Changes will be compared to basal data.
Six months
Secondary Changes in bladder volume Change in bladder volume measured in ml before and after implantation of implantable pulse generator for sacral neuromodulation Six months
Secondary Changes in bladder sensation Mangler Changes in bladder sensation measured in ml before and after implantation of implantable pulse generator for sacral neuromodulation Six months
Secondary Bowel function Bowel function by standard questionnaire ICIQ-B (04/08). Scale ranges from 0 to 75 points. Higher score indicate greater impact of individual symptoms for the patient.
Changes will be compared to basal data.
Eight months
Secondary Male sexual function Male sexual function by standard questionnaire (07/05). Scale ranges from 0 to 12 points. Higher score indicate greater impact of individual symptoms for the patient.
Changes will be compared to basal data.
Six months
Secondary Female sexual function Female sexual function by standard questionnaire (09/05). Scale ranges from 0 to 14 points. Higher score indicate greater impact of individual symptoms for the patient.
Changes will be compared to basal data.
Six months
Secondary Quality of life by standard questionnaire EQ-5D-5L The EQ-5D-5L is a standard measure of health-related quality of life. EQ-5D-5L consists of two components: a health state profile and a visual analog scale (VAS). EQ-5D health state profile comprises 5 dimensions:
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems.
The 5D-5L systems are converted into a single index utility score between 0 to 1, where a higher score indicates a better health state.
The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine". Higher scores of EQ VAS indicate better health
Six months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4